R&D | January 14, 2026
Avista Therapeutics unveils AI-powered expansion of gene therapy platform
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
